Accueil Recherche NouveautésEmail webmaster Tous les textes - FMCSommaire généralPage précédente
Combined corticosteroid and antiviral treatment for Bell palsy
A systematic review and meta-analysis.

JAMA. 2009 Sep 2;302(9):1003-4.
de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, Chen JM.
Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, Canada.

Revoir la paralysie faciale
[Lire]


En conclusion de cette méta analyse, il apparaît que le traitement de la paralysie faciale essentielle, en 2009, repose sur une combinaison de stéroïdes et d'antiviraux (anti herpétiques).

CONTEXT: New evidence has emerged regarding the use of corticosteroids and antiviral agents in Bell palsy.

OBJECTIVE: To estimate the association of corticosteroids and antiviral agents with the risk of unsatisfactory facial recovery in patients with Bell palsy. DATA SOURCES: The search included MEDLINE, EMBASE, CENTRAL, PsychInfo, CINAHL, Web of Science, PAPERSFIRST, PROCEEDINGSFIRST, and PROQUEST to identify studies up to March 1, 2009.

STUDY SELECTION AND DATA EXTRACTION: Eligible studies were randomized controlled trials comparing treatment with either corticosteroids or antiviral agents with a control and measuring at least 1 of the following outcomes: unsatisfactory facial recovery (> or = 4 months), unsatisfactory short-term recovery (6 weeks to < 4 months), synkinesis and autonomic dysfunction, or adverse effects. Two reviewers extracted data on study characteristics, methods, and outcomes. Disagreement was resolved by consensus.

RESULTS: Eighteen trials involving 2786 patients were eligible. Regression analysis identified a synergistic effect when corticosteroids and antiviral agents were administered in combination compared with alone (odds ratio for interaction term, 0.54 [95% confidence interval {CI}, 0.35-0.83]; P = .004). Meta-analysis using a random-effects model showed corticosteroids alone were associated with a reduced risk of unsatisfactory recovery (relative risk [RR], 0.69 [95% CI, 0.55-0.87]; P = .001) (number needed to treat to benefit 1 person, 11 [95% CI, 8-25]), a reduced risk of synkinesis and autonomic dysfunction (RR, 0.48 [95% CI, 0.36-0.65]; P < .001) (number needed to treat to benefit 1 person, 7 [95% CI, 6-10]), and no increase in adverse effects. Antiviral agents alone were not associated with a reduced risk of unsatisfactory recovery (RR, 1.14 [95% CI, 0.80-1.62]; P = .48). When combined with antiviral agents, corticosteroids were associated with greater benefit (RR, 0.48 [95% CI, 0.29-0.79]; P = .004) than antiviral agents alone.
When combined with corticosteroids, antiviral agents were associated with greater risk reduction of borderline significance compared with corticosteroids alone (RR, 0.75 [95% CI, 0.56-1.00]; P = .05).

CONCLUSIONS: In Bell palsy, corticosteroids are associated with a reduced risk of unsatisfactory recovery. Antiviral agents, when administered with corticosteroids, may be associated with additional benefit.

PMID: 19724046 [PubMed - indexed for MEDLINE]
.
Accueil NouveautésEmail webmaster Sommaire FMC Sommaire généralPage précédente